The threat from the pink corner

References

• Livermore DM, Mushtaq S, James D, Potz N, Walker RA, Charlett A, et al. In-vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents 2003: in press.
   PubMed Web of Science ®Google Scholar
• Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213–6.
   PubMed Web of Science ®Google Scholar
• Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(2 Suppl): 397S–404S.
   Google Scholar
• Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin — United States, 2002. MMWR 2002; 51: 565–7.
   PubMedGoogle Scholar
• Gruneberg RN. Global surveillance through PROTEKT: the first year. J Chemother 2002; 14 Suppl 3: 9–16.
   PubMed Web of Science ®Google Scholar
• Livermore DM. The impact of carbapenemases on antimi-crobial development and therapy. Curr Opin Investig Drugs 2002; 3: 218–24.
   PubMedGoogle Scholar
• Johnson AP, Livermore DM, Tillotson GS. Antimicrobial susceptibility of gram-positive bacteria: what's current, what's anticipated? J Hosp Infect 2001; 49 Suppl A: S3–11.
   Google Scholar
• Garau J. Treatment of drug-resistant pneumococcal pneumo-nia. Lancet Infect Dis 2002; 2: 404–15.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare? Clin Infect Dis 2002; 34: 631 10.
   Google Scholar
• Henwood CJ, Livermore DM, James D, Warner M, Pseudomonas Study Group. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evalu-ation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 2001; 47: 789–99.
   PubMed Web of Science ®Google Scholar
• Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 521–34.
   Google Scholar
• Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251–4.
   PubMed Web of Science ®Google Scholar
• Nordmatm P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321–31.
   PubMed Web of Science ®Google Scholar
• Danel F, Hall LM, Giir D, Akalin HE, Livermore DM. Transferable production of PER-1 P-lactamase in Pseudomo-nas aeruginosa. J Antimicrob Chemother 1995; 35: 281–94.
   Google Scholar
• Naas T, Nordmann P. OXA-type P-lactamases. Curr Pharm Des 1999; 5: 865–79.
   Google Scholar
• Tsalcris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38: 1290–2.
   PubMed Web of Science ®Google Scholar
• Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicici W, Livermore DM, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla (IMP) allele, bla (IMP-7). Antimicrob Agents Chemother 2002; 46: 255–8.
   PubMed Web of Science ®Google Scholar
• Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960–7.
   PubMed Web of Science ®Google Scholar
• Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudo-monas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008–11.
   PubMed Web of Science ®Google Scholar
• Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epide-miological features. Clin Microbiol Rev 1996; 9: 148–65.
   PubMed Web of Science ®Google Scholar
• Afzal-Shah M, Woodford N, Livermore DM. Characteriza-tion of: OXA-25, -26 and -27 molecular Class D P-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583–8.
   Google Scholar
• Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem re-sistance in A. baumannii is not due solely to the presence of p-lactamases. J Clin Microbiol 2000; 38: 3299–305.
   PubMed Web of Science ®Google Scholar
• Lopez-Otsoa F, Gallego L, Towner KJ, Tysall L, Woodford N, Livermore DM. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in Northern Spain. J Clin Microbiol 2002; 40: 4741–3.
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence R, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479–87.
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus P-lactams, aminogly-cosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946–52.
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneu-monia. Clin Infect Dis 2002; 34: 1425–30.
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793–802.
   PubMed Web of Science ®Google Scholar
• Bello H, Dominguez M, Gonzalez G, Zemelman R, MeIla S, Young HK, et al. In-vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii com-plex isolated in Chile between 1990 and 1998. J Antimicrob Chemother 2000; 45: 712–3.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Livermore DM. Effect of media composition on the susceptibility of Xanthomonas maltophilia to j3-lactam antibiotics. J Antimicrob Chemother 1991; 28: 837–42.
   PubMed Web of Science ®Google Scholar
• VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomo-nas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997; 18: 316–21.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32: 651–6.
   PubMedGoogle Scholar
• Munoz Bellido JL, Garcia-Rodriguez JA. Aztreonam-clavu-lanic acid synergy does not mean extended-spectrum 3-lactamase in Stenotrophomonas maltophilia. J Antimicrob Chemother 1998; 41: 493–4.
   PubMed Web of Science ®Google Scholar
• Garcia Sanchez JE, Vazquez Lopez ML, Blazquez de Castro AM, Perez Simon JA, Gutierrez NG, Martin IT, et al. Aztreonam/clavulanic acid in the treatment of serious infec-tions caused by Stenotrophomonas maltophilia in neutropenic patients: case reports. J Chemother 1997; 9: 238–40.
   Google Scholar
• Downhour NP, Petersen EA, Krueger TS, Tangella KY, Nix DE. Severe cellulitis/myositis caused by Stenotrophomonas maltophilia. Ann Pharmacother 2002; 36: 63–6.
   Google Scholar
• Ho PL, Cheung TK, Yam WC, Yuen KY. Characterization of a laboratory-generated variant of BPS 3-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother 2002; 50: 723–6.
   PubMed Web of Science ®Google Scholar
• Niumsup P, Wuthiekanun V. Cloning of the class D 3-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J Antimicrob Chemother 2002; 50: 445–55.
   PubMed Web of Science ®Google Scholar
• Cheung TK, Ho PL, Woo PC, Yuen KY, Chau PY. Cloning and expression of class A 3-lactamase gene blaA (BPS) in Burkholderia pseudomallei. Antimicrob Agents Chemother 2002; 46: 1132–5.
   PubMed Web of Science ®Google Scholar
• Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001; 3: 255–64.
   PubMed Web of Science ®Google Scholar
• Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 1999; 43: 465–70.
   PubMed Web of Science ®Google Scholar
• Baxter IA, Lambert PA. Isolation and partial purification of a carbapenem-hydrolysing metallo-3-lactamase from Pseudo-monas cepacia. FEMS Microbiol Lett 1994; 122: 251–6.
   PubMed Web of Science ®Google Scholar
• Pitt TL, Kaufmann ME, Patel PS, Benge LC, Gaslcin S, Livermore DM. Type characterisation and antibiotic suscep-tibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996; 44: 203–10.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for pa-tients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206–12.
   Google Scholar
• Koh TH, Sng LH, Babini GS, Woodford N, Livermore DM, Hall LMC. Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 3-lactamase and lacking an outer membrane protein. Antimicrob Agents Chemother 2001; 45: 1939–40.
   PubMed Web of Science ®Google Scholar
• Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-3-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Anti-microb Chemother 2002; 50: 503–11.
   PubMed Web of Science ®Google Scholar
• Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying b/a(IMP-8) in a university medical center in Taiwan. J Clin Microbiol 2001; 39: 4433–9.
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Xiong J, Ye H, Li H, M'Zali FH. Occurrence of a new metallo-3-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194: 53–7.
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing B-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemo-ther 2001; 45: 1151–61.
   Google Scholar
• Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002; 5: 119–25.
   PubMed Web of Science ®Google Scholar
• Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45: 363–5.
   Google Scholar
• Critchley IA, Basker MJ, Edmondson RA, Knott SJ. Uptake of a catecholic cephalosporin by the iron transport system of Escherichia coli. J Antimicrob Chemother 1991; 28: 377–88.
   PubMed Web of Science ®Google Scholar
• Giacometti A, Cirioni 0, Del Prete MS, Barchiesi F, Paggi AM, Petrelli E, et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter bau-mannii. J Antimicrob Chemother 2000; 46: 807–10.
   Google Scholar
• Giacometti A, Cirioni 0, Del Prete MS, Barchiesi F, Fortuna M, Drenaggi D, et al. In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44: 1716–9.
   Google Scholar
• Giacometti A, Cirioni 0, Barchiesi F, Fortuna M, Scalise G. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 641–5.
   Google Scholar
• Lomovskaya 0, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aerugi-nosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105–16.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Du W, Bateson JH. 3-Lactamase epidemiology and the utility of established and novel 3-lactamase inhibitors. Expert Opin Investig Drugs 2000; 9: 247–61.
   PubMed Web of Science ®Google Scholar